Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.

p53, guardian of the genome

Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138

Participation of p53 protein in the cellular response to DNA damage.

Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761

Proposals for the classification of the myelodysplastic syndromes

Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619

Molecular themes in oncogenesis

Bishop, J. M. (1991) · Cell · doi:10.1016/0092-8674(91)90636-d · Cited by 1,629

Clinical Implications of the p53 Tumor-Suppressor Gene

Harris, C. C., & Hollstein, M. C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291807 · Cited by 1,317

Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?

Stein, C., & Cheng, Y. C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,300

Presence of a Potent Transcription Activating Sequence in the p53 Protein

Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790

Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene

Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 620

Wild-type p53 can down-modulate the activity of various promoters.

Ginsberg, D., Mechta‐Grigoriou, F., Yaniv, M., & Oren, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.9979 · Cited by 434

p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis

Greiner, T., Moynihan, M., Chan, W., Lytle, D. M., Pedersen, A., Anderson, J., & Weisenburger, D. D. (1996) · Blood · doi:10.1182/blood.v87.10.4302.bloodjournal87104302 · Cited by 285

p53 in hematologic malignancies

Imamura, J., Miyoshi, I., & Koeffler, H. (1994) · Blood · doi:10.1182/blood.v84.8.2412.bloodjournal8482412 · Cited by 261

Human p53 gene localized to short arm of chromosome 17

Miller, C. W., Mohandas, T. K., Wolf, D., Prokocimer, M., Rotter, V., & Koeffler, H. P. (1986) · Nature · doi:10.1038/319783a0 · Cited by 215

Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages

Prokocimer, M., & Rotter, V. (1994) · Blood · doi:10.1182/blood.v84.8.2391.bloodjournal8482391 · Cited by 185

Separation of synthetic phosphorothioate oligodeoxynucleotides from their oxygenated (phosphodiester) defect species by strong-anion-exchange high-performance liquid chromatography

Bergot, B. J., & Egan, W. (1992) · Journal of Chromatography A · doi:10.1016/0021-9673(92)85456-4 · Cited by 82

Expression of the p53 oncogene in acute myeloblastic leukemia.

Smith, L. J., McCulloch, E. A., & Benchimol, S. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.164.3.751 · Cited by 52

Selective Cytotoxicity to Human Leukemic Myeloblasts Produced by Oligodeoxyribonucleotide Phosphorothioates Complementary to p53 Nucleotide Sequences

Bayever, E., Haines, K. M., Iversen, P. L., Ruddon, R. W., Pirruccello, S. J., Mountjoy, C. P., Arneson, M. A., & Smith, L. J. (1994) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199409059593 · Cited by 48

A denaturing gradient gel electrophoresis assay for sensitive detection of p53 mutations

Beck, J., Kwitek, A. E., Cogen, P. H., Metzger, A. K., Duyk, G. M., & Sheffield, V. C. (1993) · Human Genetics · doi:10.1007/bf00230217 · Cited by 41

Antisense Oligonucleotide Therapies: Are They the “Magic Bullets”?

Ma, D. D. F., & Doan, T. L. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-2-199401150-00010 · Cited by 24

OMA-AML-1: a leukemic myeloid cell line with CD34+ progenitor and CD15+ spontaneously differentiating cell compartments

Pirruccello, S. J., Jackson, J., Lang, M., DeBoer, J. M., Mann, S., Crouse, D. A., Wp, V., Ka, D., & Sharp, J. G. (1992) · Blood · doi:10.1182/blood.v80.4.1026.bloodjournal8041026 · Cited by 9

Antisense oligonucleotide OL (1) p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia.

Bishop, M. R., Warkentin, P., Jackson, J. D., Bayever, E., Iversen, P. L., Whalen, V. I., Lastovica, J., Haines, K. M., & Kessinger, A. (1994) · PubMed · Cited by 5

Nucleic-acid therapeutics: basic principles and recent applications

Opalinska, J., & Gewirtz, A. M. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd837 · Cited by 535

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

Webb, A., Cunningham, D., Cotter, F. E., Clarke, P. A., Stefano, F. D., Ross, P. J., Corbo, M., & Dziewanowska, Z. E. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11103-x · Cited by 490

Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma

Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F. I., Stefano, F. D., & Cotter, F. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1812 · Cited by 454

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396

Antisense therapy for cancer

Gleave, M. E., & Monia, B. P. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1631 · Cited by 384

Nucleic Acid Therapeutics: State of the Art and Future Prospects

Gewirtz, A. M., Sokol, D. L., & Ratajczak, M. Z. (1998) · Blood · doi:10.1182/blood.v92.3.712 · Cited by 249

A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

Chi, K. N., Gleave, M. E., Klasa, R. J., Murray, N., Bryce, C. J., de Menezes, D. E. L., D’Aloisio, S., & Tolcher, A. W. (2001) · PubMed · Cited by 192

Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer

Nemunaitis, J. J., Holmlund, J., Kraynak, M. A., Richards, D., Bruce, J., Ognoskie, N., Kwoh, T. J., Geary, R. S., Dorr, A., Hoff, D. V., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3586 · Cited by 172

RNA-targeted therapeutics in cancer clinical trials: Current status and future directions

Barata, P. C., Sood, A. K., & Hong, D. S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.004 · Cited by 153

Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.

Yuen, A. R., Halsey, J., Fisher, G. A., Holmlund, J. T., Geary, R. S., Kwoh, T. J., Dorr, A., & Sikic, B. I. (1999) · PubMed · Cited by 148

Apoptosis caused by oxidized LDL is manganese superoxide dismutase and p53 dependent

Kinscherf, R., Claus, R. A., Wagner, M., Gehrke, C., Kamencic, H., Hou, D., Nauen, O., Schmiedt, W., Kovács, G., Pill, J., et al. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.6.461 · Cited by 133

Antisense and siRNA as agonists of Toll-like receptors

Agrawal, S., & Kandimalla, E. R. (2004) · Nature Biotechnology · doi:10.1038/nbt1042 · Cited by 132

Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)

Stevenson, J. P., Yao, K.-S., Gallagher, M., Friedland, D. P., Mitchell, E. P., Cassella, A., Monia, B. P., Kwoh, T. J., Yu, R. Z., Holmlund, J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2227 · Cited by 129

A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies

Rosenfeld, C. S., & List, A. F. (2000) · Leukemia · doi:10.1038/sj.leu.2401618 · Cited by 119

Tumor Protein p53 (TP53) Testing and Li-Fraumeni Syndrome

Sorrell, A., Espenschied, C. R., Culver, J. O., & Weitzel, J. N. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0020-0 · Cited by 109

Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor

Asaoka, K., Tada, M., Sawamura, Y., Ikeda, J., & Abe, H. (2000) · Journal of neurosurgery · doi:10.3171/jns.2000.92.6.1002 · Cited by 103

Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Oligonucleotides in Mice

Zhao, Q., Temsamani, J., ZHOU, R.-Z., & Agrawal, S. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.495 · Cited by 100

Tetranucleotide GGGA Motif in Primary RNA Transcripts

Tu, G.-C., Cao, Q.-N., Zhou, F., & Israel, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.39.25125 · Cited by 93

Myelodysplasic syndromes: A comprehensive review

Catenacci, D. V. T., & Schiller, G. J. (2005) · Blood Reviews · doi:10.1016/j.blre.2005.01.004 · Cited by 89

Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides

White, P. J., Anastasopoulos, F., Pouton, C. W., & Boyd, B. J. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001021 · Cited by 87

Overview of the clinical efficacy of investigational anticancer drugs

Nygren, P., & Larsson, R. L. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01098.x · Cited by 79

Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study

Luger, S. M., O’Brien, S. G., Ratajczak, J., Ratajczak, M. Z., Mick, R., Stadtmauer, E. A., Nowell̀, P. C., Goldman, J. M., & Gewirtz, A. M. (2002) · Blood · doi:10.1182/blood.v99.4.1150 · Cited by 77

Antisense to the Epstein-Barr Virus (EBV)-Encoded Latent Membrane Protein 1 (LMP-1) Suppresses LMP-1 and Bcl-2 Expression and Promotes Apoptosis in EBV-Immortalized B Cells

Kenney, J. L., Guinness, M. E., Curiel, T. J., & Lacy, J. (1998) · Blood · doi:10.1182/blood.v92.5.1721 · Cited by 69

Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies

Jen, K., & Gewirtz, A. M. (2000) · Stem Cells · doi:10.1634/stemcells.18-5-307 · Cited by 67

The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target

Cheung, K. J., Horsman, D. E., & Gascoyne, R. D. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07739.x · Cited by 62

Human Bcl-2 antisense therapy for lymphomas

Cotter, F. E., Waters, J. S., & Cunningham, D. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00139-6 · Cited by 61

Antisense therapeutics: lessons from early clinical trials

Flaherty, K. T., Stevenson, J. P., & O'Dwyer, P. J. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00013 · Cited by 61

In vivo imaging with oligonucleotides for diagnosis and drug development

Tavitian, B. (2003) · Gut · doi:10.1136/gut.52.suppl_4.iv40 · Cited by 57

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients

Cáceres, G., McGraw, K. L., Yip, B. H., Pellagatti, A., Johnson, J., Zhang, L., Liu, K., Zhang, L. M., Fulp, W. J., Lee, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311055110 · Cited by 57

Inhibition of P-Glycoprotein and Recovery of Drug Sensitivity of Human Acute Leukemic Blast Cells by Multidrug Resistance Gene (mdr1) Antisense Oligonucleotides

Motomura, S., Motoji, T., Takanashi, M., Wang, Y., Shiozaki, H., Sugawara, I., Aikawa, E., Tomida, A., Tsuruo, T., Kanda, N., et al. (1998) · Blood · doi:10.1182/blood.v91.9.3163 · Cited by 51

Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset

Kronenwett, R., Steidl, U. U., Kirsch, M., Sczakiel, G., & Haas, R. R. (1998) · Blood · doi:10.1182/blood.v91.3.852 · Cited by 51

p53-Oriented cancer therapies: Current progress

Gallagher, W. M., & Brown, R. E. (1999) · Annals of Oncology · doi:10.1023/a:1008368500557 · Cited by 51

Antisense raf Oligodeoxyribonucleotide Is a Radiosensitizer In Vivo

Gokhale, P. C., McRae, D. A., Monia, B. P., Bagg, A., RAHMAN, A., Dritschilo, A., & Kasid, U. N. (1999) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1999.9.191 · Cited by 50

G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma

van de Donk, N. W. C. J., de Weerdt, O., Veth, G., Eurelings, M., van Stralen, E., Frankel, S. R., Hagenbeek, A., Bloem, A. C., & Lokhorst, H. M. (2004) · Leukemia · doi:10.1038/sj.leu.2403363 · Cited by 47

Oligonucleotide Therapeutics: A Step Forward

Gewirtz, A. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1809 · Cited by 46

Pharmacokinetics and Tolerability of Intravenous Trecovirsen (GEM®91), an Antisense Phosphorothioate Oligonucleotide, in HIV‐Positive Subjects

Séréni, D., Tubiana, R., Lascoux‐Combe, C., Katlama, C., Taulera, O., Bourque, A. J., Cohen, A. S., Dvorchik, B. H., Martin, R. R., Tournerie, C., et al. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922007552 · Cited by 44

Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-κB/Rel− specific decoy oligodeoxynucleotides

Romano, M. F., Lamberti, A., Bisogni, R., Tassone, P., Pagnini, D., Storti, G., Vecchio, L. D., Turco, M. C., & Venuta, S. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301216 · Cited by 42

Cellular Distribution of Phosphorothioate Oligonucleotide Following Intravenous Administration in Mice

Zhao, Q., ZHOU, R.-Z., Temsamani, J., ZHANG, Z., Roskey, A., & Agrawal, S. (1998) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1998.8.451 · Cited by 42

Developing antisense oligonucleotides from the laboratory to clinical trials

Szymkowski, D. E. (1996) · Drug Discovery Today · doi:10.1016/s1359-6446(96)80008-0 · Cited by 42

Toxicologic Effects of an Oligodeoxynucleotide Phosphorothioate and Its Analogs Following Intravenous Administration in Rats

Agrawal, S., Zhao, Q., JIANG, Z., OLIVER, C., GILES, H., HEATH, J., & Serota, D. G. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.575 · Cited by 41

A Phase II Trial of ISIS 3521 in Patients with Metastatic Colorectal Cancer

Marshall, J. L., Eisenberg, S. G., Johnson, M. D., Hanfelt, J., Dorr, F. A., El‐Ashry, D., Oberst, M. D., Fuxman, Y., Holmlund, J., & Malik, S. M. (2004) · Clinical Colorectal Cancer · doi:10.3816/ccc.2004.n.026 · Cited by 40

Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems

Clark, R. E. (2000) · Leukemia · doi:10.1038/sj.leu.2401677 · Cited by 39

Ribosomopathies: New Therapeutic Perspectives

Orgebin, E., Lamoureux, F., Isidor, B., Charrier, C., Ory, B., Lézot, F., & Baud’huin, M. (2020) · Cells · doi:10.3390/cells9092080 · Cited by 38

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

Cortes, J., Kantarjian, H., Ball, E. D., DiPersio, J., Kolitz, J. E., Fernandez, H. F., Goodman, M., Borthakur, G., Baer, M. R., & Wetzler, M. (2012) · Cancer · doi:10.1002/cncr.26292 · Cited by 37

Pharmacokinetics and Metabolism of an Oligodeoxynucleotide Phosphorothioate (GEM91®) in Cynomolgus Monkeys Following Intravenous Infusion

Grindel, J. M., Musick, T. J., JIANG, Z., Roskey, A., & Agrawal, S. (1998) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1998.8.43 · Cited by 36

Clinical studies of antisense therapy in cancer

Alan, R. Y. (2000) · Frontiers in bioscience · doi:10.2741/yuen · Cited by 36

Antisense Therapy: Current Status in Prostate Cancer and Other Malignancies

Gleave, M. E., Miyake, H., Zangemeister‐Wittke, U., & Jansen, B. (2002) · Cancer and Metastasis Reviews · doi:10.1023/a:1020172424152 · Cited by 35

Therapeutic Efficacy of Adenoviral-Mediated p53 Gene Transfer Is Synergistically Enhanced by Combined Use of Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model

Miyake, H., Yamanaka, K., Muramaki, M., Hara, I., & Gleave, M. E. (2005) · Neoplasia · doi:10.1593/neo.04478 · Cited by 34

Ex Vivo Treatment of Bone Marrow with Phosphorothioate Oligonucleotide OL(l)p53 for Autologous Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Bishop, M. R., JACKSON, J. D., Tarantolo, S., O'KANE-MURPHY, B., Iversen, P. L., Bayever, E., JOSHI, S. M., Sharp, J. G., Pierson, J. L., Warkentin, P. I., et al. (1997) · Journal of Hematotherapy · doi:10.1089/scd.1.1997.6.441 · Cited by 33

Transdermal delivery of antisense compounds

Brand, R. M., & Iversen, P. L. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00083-1 · Cited by 32

New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway

van de Donk, N. W. C. J., Bloem, A. C., van der Spek, E., & Lokhorst, H. M. (2005) · Current Pharmaceutical Design · doi:10.2174/138161206775201974 · Cited by 29

Cell cycle-dependent distribution and specific inhibitory effect of vectorized antisense oligonucleotides in cell culture

Hélin, V., Gottikh, M., Mishal, Z., Subra, F., Malvy, C., & Lavignon, M. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00083-0 · Cited by 29

Bolus Intravenous Injection of Phosphorothioate Oligonucleotides Causes Hypotension by Acting as α1-Adrenergic Receptor Antagonists

Iversen, P. L., Cornish, K. G., Iversen, L. J., Mata, J. E., & Bylund, D. B. (1999) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1999.8771 · Cited by 29

DNA and RNA derivatives to optimize distribution and delivery

Wickstrom, E. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.012 · Cited by 28

Endocrine Aspects of Cancer Gene Therapy

Barzon, L., Boscaro, M., & Palù, G. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0035 · Cited by 27

Antisense cancer therapy: The state of the science

Kushner, D. M., & Silverman, R. H. (2000) · Current Oncology Reports · doi:10.1007/s11912-000-0007-y · Cited by 27

Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors

Engelhard, H. H. (1998) · Cancer Control · doi:10.1177/107327489800500207 · Cited by 27

Clinical evaluation of biologically targeted drugs: Obstacles and opportunities

Boral, A. L., Dessain, S. K., & Chabner, B. A. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051075 · Cited by 27

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches

Armstrong, R. N., Steeples, V., Singh, S., Sanchi, A., Boultwood, J., & Pellagatti, A. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.09.008 · Cited by 30

Antisense therapy for lymphomas

Cotter, F. E. (1997) · Hematological Oncology · doi:10.1002/(sici)1099-1069(199702)15:1 · Cited by 26

PP2A: The Achilles Heal in MDS with 5q Deletion

Sallman, D. A., Sheng, W., & List, A. F. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00264 · Cited by 26

Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences

Venugopal, S., Mascarenhas, J. O., & Steensma, D. P. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100735 · Cited by 26

Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1α-oligonucleotide

Park, Y. S., Huang, Y., Park, Y. J., David, A. E., White, L. R., He, H., Chung, H. S., & Yang, V. C.-M. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.026 · Cited by 25

Gene Delivery by Liposomes

Nordling‐David, M. M., & Golomb, G. (2013) · Israel Journal of Chemistry · doi:10.1002/ijch.201300055 · Cited by 26

Physicochemical and biological characterisation of an antisense oligonucleotide targeted against the bcl-2 mRNA complexed with cationic–hydrophilic copolymers

Read, M. L., Dash, P. R., Clark, A. M., Howard, K. A., Oupický, D., Toncheva, V., Alpar, H. O., Schacht, E. H., Ulbrich, K., & Seymour, L. W. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00069-5 · Cited by 24

Oligonucleotide therapeutics for hematologic disorders

Agarwal, N., & Gewirtz, A. M. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00142-6 · Cited by 24

Antisense strategies for the treatment of hematological malignancies and solid tumors

Kronenwett, R., & Haas, R. R. (1998) · Annals of Hematology · doi:10.1007/s002770050404 · Cited by 22

Antisense Oligonucleotides in Cancer

Lebedeva, I. V., & Stein, C. A. (2000) · BioDrugs · doi:10.2165/00063030-200013030-00005 · Cited by 21

Biodistribution and Metabolism of a Mixed Backbone Oligonucleotide (GEM 231) Following Single and Multiple Dose Administration in Mice

Rusckowski, M., QU, T., Roskey, A., & Agrawal, S. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.333 · Cited by 20

Antisense oligonucleotide therapeutics

Bennett, C. F. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.3.237 · Cited by 20

Antisense‐induced down‐regulation of thymidylate synthase and enhanced cytotoxicity of 5‐FUdR in 5‐FUdR‐resistant HeLa cells

Ferguson, P. J., DeMoor, J. M., Vincent, M. D., & Koropatnick, J. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704394 · Cited by 19

Cellular Uptake Properties of Oligonucleotides in LLC- PK 1 Renal Epithelial Cells

Takakura, Y., OKA, Y., & Hashida, M. (1998) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1998.8.67 · Cited by 19

Antisense oligonucleotides and RNAs as modulators of pre-mRNA splicing

Sierakowska, H., Gorman, L. Z., Kang, S.-H., & Kole, R. (2000) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(00)13032-0 · Cited by 19

Molecular technology and pancreatic cancer

Manu, M., BUCKELS, J. A. C., & Bramhall, S. R. (2000) · British journal of surgery · doi:10.1046/j.1365-2168.2000.01510.x · Cited by 19

Methods in Molecular Biology TM

Martin, S. G., Murray, C., Hewitson, T. D., Becker, G. J., Brown, C., & Vančura, A. (2008) · Cited by 18

Phosphorothioate Oligodeoxynucleotides: Large‐Scale Synthesis and Analysis, Impurity Characterization, and the Effects of Phosphorus Stereochemistry

Fearon, K. L., Hirschbein, B. L., Chiu, C., Quijano, M. R., & Zon, G. (2007) · Novartis Foundation symposium · doi:10.1002/9780470515396.ch3 · Cited by 18

Antisense - time to shoot the messenger

Kuss, B. J., & Cotter, F. E. (1999) · Annals of Oncology · doi:10.1023/a:1026416314887 · Cited by 18

Current Status of Ribozymes as Gene Therapy Agents for Cancer

Wright, L., & Kearney, P. (2001) · Cancer Investigation · doi:10.1081/cnv-100103848 · Cited by 18

Modification of pre-mRNA splicing by antisense oligonucleotides.

Kole, R. (1997) · Acta Biochimica Polonica · doi:10.18388/abp.1997_4418 · Cited by 17

Etiopathogeny, prognosis and therapy of myelodysplastic syndromes

Sanz, G. F., Sanz, M. Á., & Vallespı́, T. (1997) · Hematology and Cell Therapy · doi:10.1007/s00282-997-0277-z · Cited by 17

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

Lanasa, M. C., Davis, P. H., Datto, M., Li, Z., Gockerman, J. P., Moore, J. O., DeCastro, C. M., Friedman, D. R., Diehl, L. F., Rehder, C., et al. (2012) · Leukemia & Lymphoma · doi:10.3109/10428194.2011.610012 · Cited by 16

Evidence of Enhanced Iron Excretion During Systemic Phosphorothioate Oligodeoxynucleotide Treatment

Mata, J. E., Bishop, M. R., Tarantolo, S., Angle, C. R., Swanson, S. A., & Iversen, P. L. (2000) · Journal of Toxicology Clinical Toxicology · doi:10.1081/clt-100100947 · Cited by 16

MOLECULAR TARGETS FOR THE THERAPEUTIC MANIPULATION OF APOPTOSIS IN BLADDER CANCER

Duggan, B. J., Kelly, J. D., KEANE, P. F., & Johnston, S. R. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)66582-2 · Cited by 16

Antisense Oligonucleotides as Modulators of Pre-mRNA Splicing

Sierakowska, H., Agrawal, S., & Kole, R. (2003) · Humana Press eBooks · doi:10.1385/1-59259-215-5:223 · Cited by 15

CD40 and B Chronic Lymphocytic Leukemia Cell Response To Fludarabine: The Influence of NF-kB/Rel Transcription Factors On Chemotherapy-Induced Apoptosis

Romano, M. F., Lamberti, A., Turco, M. C., & Venuta, S. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009148846 · Cited by 14

Antisense Oligonucleotide-based Therapeutics

Hardee, G. E., Swayze, E. E., Mehta, R., Teng, C., Levin, A. A., Bennett, C. F., Tillman, L., & Geary, R. S. (2003) · CRC Press eBooks · doi:10.1201/9780824758608.ch19 · Cited by 13

Use of Antisense Vectors and Oligodeoxynucleotides in Neuro-Oncology

Engelhard, H. H., Egli, M., & Rozental, J. M. (1998) · Pediatric Neurosurgery · doi:10.1159/000028665 · Cited by 12

Combination of antisense oligonucleotide and low-dose chemotherapy in hematological malignancies

Benner, E. J., Bishop, M. R., Agarwal, N., Iversen, P. L., & Joshi, S. S. (1997) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(97)00034-8 · Cited by 12

Restoration of ß-Globin Gene Expression in Mammalian Cells by Antisense Oligonucleotides That Modify the Aberrant Splicing Patierns of Thalassemic Pre-mRNAs

Sierakowska, H., Montague, M. G., Agrawal, S., & Kole, R. (1997) · Nucleosides and Nucleotides · doi:10.1080/07328319708006154 · Cited by 12

Pharmacokinetic Properties of Phosphorothioate Oligonucleotides in Humans

Leeds, J. M., & Geary, R. S. (1998) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-58785-6_6 · Cited by 12

Determination of cellular uptake and intracellular levels of Cenersen (Aezea®, EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells

Alachkar, H., Xie, Z., Marcucci, G., & Chan, K. K. (2012) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2012.08.011 · Cited by 11

Topical Iontophoretic Delivery

Hirvonen, J. J. (2005) · American Journal of Drug Delivery · doi:10.2165/00137696-200503020-00001 · Cited by 11

Pharmacology of Therapeutic Oligonucleotides

Diasio, R. B., & Zhang, R. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.239 · Cited by 11

Cancer Gene Therapy: Part 2. Candidate Transgenes and their Clinical Development

Harrington, K. J., Melcher, A. A., Bateman, A. R., Ahmed, A. U., & Vile, R. G. (2002) · Clinical Oncology · doi:10.1053/clon.2001.0004 · Cited by 10

In Vivo Pro-Apoptotic and Antitumor Efficacy of a c-Raf Antisense Phosphorothioate Oligonucleotide: Relationship to Tumor Size

Lau, Q. C., Achenbach, T. V., Borchers, O., Müller, R., & Slater, E. P. (2002) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729002753670229 · Cited by 10

Single‐injection ornithine decarboxylase‐directed antisense therapy using atelocollagen to suppress human cancer growth

Nakazawa, K., Nemoto, T., Hata, T., Seyama, Y., Nagahara, S., Sano, A., Itoh, H., Nagai, Y., & Kubota, S. (2007) · Cancer · doi:10.1002/cncr.22483 · Cited by 9

Antisense oligonucleotides complementary to immunoglobulin sequences of BCL-2/immunoglobulin fusion transcript induce apoptosis of t(14;18) lymphoma cells

Smith, M. R., Xie, T., Zhou, Z., & Joshi, I. D. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02431.x · Cited by 9

Is Myelodysplastic Related Acute Myelogenous Leukemia a Distinct Entity from de novo Acute Myelogenous Leukemia? Potential for Targeted Therapies

Rosenfeld, C. S., & Kantarjian, H. M. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109060340 · Cited by 8

Antisense approaches in drug discovery and development

Rayburn, E. R., Wang, W., Zhang, R., & Wang, H. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7414-4_10 · Cited by 8

Lack of toxicity associated with the systemic administrat of antisense oligonucleotides for treatment of rats bearing LNCaP prostate tumors

Rubenstein, M., Mirochnik, Y., Ray, V., & Guinan, P. (1997) · Medical Oncology · doi:10.1007/bf02989639 · Cited by 8

Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial

Bayever, E., Iversen, P. L., Bishop, M. R., Sharp, J. G., Tewary, H. K., Arneson, M. A., Pirruccello, S. J., Ruddon, R. W., Kessinger, A., Zon, G., et al. (1993) · Antisense Research and Development · doi:10.1089/ard.1993.3.383 · Cited by 149

Oligonucleotide Enhanced Cytotoxicity of Idarubicin for Lymphoma Cells

Sharp, J. G., Bishop, M. R., Copple, B. L., Greiner, T. C., Iversen, P. L., Jackson, J. D., Joshi, S. S., Benner, E. J., MANN, S. L., Rao, A. K., et al. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109064599 · Cited by 6

Selective Cytotoxicity to Human Leukemic Myeloblasts Produced by Oligodeoxyribonucleotide Phosphorothioates Complementary to p53 Nucleotide Sequences

Bayever, E., Haines, K. M., Iversen, P. L., Ruddon, R. W., Pirruccello, S. J., Mountjoy, C. P., Arneson, M. A., & Smith, L. J. (1994) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199409059593 · Cited by 48

Antisense oligonucleotide OL (1) p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia.

Bishop, M. R., Warkentin, P., Jackson, J. D., Bayever, E., Iversen, P. L., Whalen, V. I., Lastovica, J., Haines, K. M., & Kessinger, A. (1994) · PubMed · Cited by 5

Technology evaluation: leukemia therapy, University of Pennsylvania.

Rm, O. (1999) · PubMed · Cited by 3